NCT03759639 - N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 4, 2019

Primary Completion Date

November 7, 2022

Study Completion Date

November 7, 2022

Conditions

Niemann-Pick Disease, Type C

Interventions

DRUG

IB1001

IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.

Trial Locations (9)

University of Giessen, Giessen

Mayo Clinic, Rochester

Ludwig Maximilian University of Munich, München

Comenius University in Bratislva, Bratislava

Bellvitge University Hospital, Barcelona

Salford Trust, Salford

Great Ormond Street Hospital, London

Royal Free London NHS Foundation Trust, London

Royal Manchester Children's Hospital, Manchester